ver the past few years, several prospective and epidemiologic studies have indicated a role for microalbuminuria as a predictor of the risk of progression to end-stage renal disease. 1 In addition, albuminuria has been recognized as an important predictor of all-cause mortality, cardiovascular mortality, and cardiovascular events in the general population and in patients with diabetes or hypertension, independently of traditional risk factors. 1 However, little is known about whether pharmacological approaches based on microalbuminuria can improve prognosis of hypertensive patients. International guidelines suggest that initial treatment of hypertension in patients with kidney disease should include a drug acting on the renin-angiotensin system (RAS). 1 However, they do not provide specific recommendations for a second drug class when needed for achieving the target blood pressure.
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In this issue of the Journal, Matsui et al. report on the results of a prospective trial in hypertensive patients receiving olmesartan monotherapy for 12 weeks, followed by an additional use of hydrochlorothiazide or azelnidipine for 24 weeks. 2 They found that the reduction in albuminuria in the olmesartan/ hydrochlorothiazide group was significantly greater than that in the olmesartan/azelnidipine group (−43.2% vs. −24.0%, P = 0.0014). These results are in agreement with those of the GUARD study 3 in which treatment with an angiotensin-converting enzyme (ACE) inhibitor plus diuretic in hypertensive patients with diabetes and microalbuminuria, resulted in a greater reduction in albuminuria compared to treatment with ACE inhibitor plus calcium-channel blocker (CCB). According to Matsui et al., the greater reduction in albuminuria observed in the olmesartan/hydrochlorothiazide group should be mainly ascribed to the greater night-time blood pressure fall obtained with this combination. 2 However, it should be noted that in the Matsui et al. study the olmesartan/hydrochlorothiazide combination caused a significant impairment of glomerular filtration rate-not seen in the olmesartan/azelnidipine group-which was an independent predictor of the albuminuria decline. This effect may have contributed to the reduction in albuminuria through decreased filtration. Similar results were obtained in the GUARD study in which the mean rate of decline in glomerular filtration rate was slower in the patients randomized to the ACE inhibitor/CCB combination than those randomized to the ACE inhibitor/diuretic combination. 3 The greater decrease in albuminuria obtained with the RAS inhibitor/diuretic combination compared to the RAS inhibitor/ CCB treatment should be interpreted with caution. The results of the above studies do not allow us to extrapolate the results obtained to make conclusions around the potential impact on progression of kidney disease for the medications studied. Recent results from the ACCOMPLISH study shed more light on this controversial issue. 4 Also in the ACCOMPLISH trial the overall reduction of albuminuria was greater in the ACE inhibitor/diuretic group than in the ACE inhibitor/CCB group. However, patients had better chronic kidney disease outcomes when treated with the ACE inhibitor/CCB combination (2.0% events of chronic kidney disease progression) compared with the ACE inhibitor/diuretic combination (3.7%, P < 0·0001). In addition, previous results from the same study had shown that the ACE inhibitor/CCB combination was superior to the ACE inhibitor/diuretic combination in reducing cardiovascular events. 5 Reduction of urinary albumin may be a good marker of treatment efficacy in hypertensive subjects with microalbuminuria. However, this goal should not be achieved at the expense of kidney function. The data from the ACCOMPLISH study suggest that an antihypertensive therapy with a RAS blocker combined with a CCB should be considered in preference to a RAS blocker combined with hydrochlorothiazide because it slows progression of nephropathy to a greater extent. The greater decrease in albuminuria seen with the RAS blocker plus hydrochlorothiazide treatment in the Matsui et al. and the GUARD studies may only reflect the glomerular filtration rate impairment caused by the diuretic. Future trials will clarify whether the superiority of the RAS blocker/CCB combination on renal and cardiovascular outcomes also holds true for lower risk patients with urinary albumin in the normal range.
